Galmed Pharmaceuticals Ltd. (GLMD) is a prominent Israel-based biopharmaceutical organization that is particularly invested in the research, development, and commercialization of therapeutics for liver, metabolic, and inflammatory diseases. The company's primary product candidate is Aramchol, an orally administered therapy for the treatment of non-alcoholic steatohepatitis (NASH), a type of fatty liver disease.
Galmed Pharmaceuticals was established in 2000, with the main focus on the research of a fatty acid/bile acid conjugate discovered by Dr. Allen Zwebner, who once served as the company's Chief Science Officer. The unique conjugate, which is now branded as Aramchol, was the pivotal point that led to the foundation of the company. Aramchol is also being evaluated for its potential approach towards other liver-associated disorders such as Primary Biliary Cholangitis (PBC) and Hepatitis B.
The company, listed on the NASDAQ with the ticker symbol GLMD, has been recognized for its innovative work and development of unique solutions for addressing unmet medical needs. Their business model demonstrates a commitment to utilizing cutting-edge biotechnological processes for creating life-transforming drugs and treatments.
As a company that sits at the frontier of therapeutic liver disease research, Galmed Pharmaceuticals's approach to medicine begins with a comprehensive understanding of the underlying disease pathology. This scientifically disciplined approach allows them to design and develop targeted therapies that could dramatically shift the existing treatment paradigm.
Galmed Pharmaceuticals is a pioneer in the field of NASH management, a disease that currently have no FDA approved treatment and is estimated to affect up to 12% of adults in the major markets. Through rigorous development programs, GLMD is striving to bring life-changing therapeutics to the market, adhering to high scientific standards and stringent ethical policies.
They operate through internal research & development programs and in collaboration with local and global research institutions, thereby stretching the boundaries of medical science. As Galmed Pharmaceuticals continues its journey, it remains committed to the discovery and development of new pharmaceutical products that can enhance the quality and span of human life, even in the face of complex health challenges. Currently, the company is committed to continuing its clinical trials and expanding its portfolio of product candidates to treat liver diseases.